Baricitinib and ritlecitinib in alopecia areata: a nationwide prospective real-world registry study - Supplemental material
Published: 24 September 2026| Version 1 | DOI: 10.17632/x7j3bpv6r7.1
Contributors:
, Sophie C. van Helmond, Lieke van Vugt, Antoni Gostyński, Tristan H. van Dongen, Sherief R. Janmohamed, Manon Zweers, Tamar E.C. Nijsten, DirkJan Hijnen, Rick Waalboer-SpuijDescription
Supplemental material for "Baricitinib and ritlecitinib in alopecia areata: a nationwide prospective real-world registry study" (JAAD International). Data are from STA²R, a prospective multicenter Dutch registry. Contents: regrowth of eyebrows, eyelashes, body hair and beard, and nail change resolution per timepoint (Suppl. Table I); mean SALT over time (Suppl. Figure 1); and time to SALT ≤20 (Suppl. Figure 2).
Files
Institutions
- Erasmus MCSouth Holland, Rotterdam
- Maastricht University Medical CentreLimburg, Maastricht
- Spaarne GasthuisNorth Holland, Haarlem
- Ziekenhuis BernhovenNorth Brabant, Uden
- Radboud University Medical CenterGelderland, Nijmegen
Categories
Hair, Immunosuppressant, Immunosuppression, Hair Disorder, Alopecia, Patient Registry, Management of Alopecia Symptom, Hair Loss, Alopecia Areata, Real-World Knowledge, Janus Kinase